Petrelintide and enicepatide enter a separate combination study
The Phase 2 study NCT07589686 gives the petrelintide–enicepatide combination a distinct development record while preserving the identities of its two components.
Historical registration event: May 15, 2026. Written September 23 UTC as a reconstructed pipeline introduction. The record was first posted in May; this series's September observation is not the program's start date.
The Phase 2 study NCT07589686 gives the petrelintide–enicepatide combination a distinct development record while preserving the identities of its two components. It compares several combination regimens with component-treatment groups and placebo in adults with obesity or qualifying overweight, excluding people with a history of diabetes. Its primary weight comparison is at 40 weeks. Trial record.
The design can address whether combining an amylin analog with an incretin-based treatment adds a useful effect beyond the components. It also gives tolerability and discontinuation an important role in interpreting any weight findings. The registry has no outcome to report at this stage: its latest posted update, September 9, lists the study as not yet recruiting. The September 30 start and November 2027 primary completion are estimates, not confirmed dosing or promised readout dates.
The petrelintide overview and enicepatide overview retain their separate earlier histories. A combination registration should link those accounts rather than create a duplicate compound or merge their independent results. The Zealand–Roche partnership account (below) explains the shared commercial and development context, while the company accounts (below) preserve each company's dated resources.
An appropriate subsequent entry would cover an actual study start, a material design change, results or a consequential partnership decision. A revised estimated date alone would need editorial judgment before becoming another article.
Zealand Pharma — company resources
At June 30, Zealand held DKK 4.038 billion of cash and DKK 10.419 billion of marketable securities, totaling DKK 14.457 billion. First-half operating cash use was DKK 266 million, while reported profit was DKK 3.524 billion. Partnership revenue recognition and cash receipts occur on different schedules: the period included a $125 million Roche anniversary payment. Those effects make a simple annualized cash-burn calculation misleading. The report records DKK 312 million of borrowings; its detailed terms should be consulted before comparing this figure with another company's debt. Half-year report published August 13.
Roche — company resources
Roche reported CHF 5.448 billion of cash and equivalents and CHF 4.286 billion of other marketable liquidity at June 30, a combined CHF 9.734 billion. Total debt was CHF 31.805 billion; the company's net-debt measure was CHF 22.071 billion. First-half operating cash flow was CHF 7.635 billion and IFRS net income CHF 7.325 billion. The profitable group can fund research from operating businesses, but these figures do not disclose a dedicated budget for either obesity program. Its CHF 4.197 billion free-cash-flow measure is distinct from operating cash flow. Half-year report published July 23.
Roche and Zealand — petrelintide and combination development
The collaboration was announced in March 2025 and became effective in May. Zealand received $1.4 billion upfront in the second quarter of 2025. A further $250 million is scheduled across two anniversaries; the first $125 million was received in the first half of 2026. Potential development and sales milestones total up to $1.2 billion and $2.4 billion respectively and remain contingent.
The partners share profits and losses equally in the United States and Europe, with co-commercialization rights. Roche has exclusive commercialization rights elsewhere, where Zealand is eligible for tiered double-digit royalties reaching the high teens. Roche carries commercial manufacturing investment responsibilities. The program includes petrelintide alone and combinations with Roche's enicepatide; the agreement's aggregate economics should not be assigned wholly to the combination or treated as cash reserved for a single trial. Zealand 2025 annual report, partnership account, 2026 half-year cash receipt.
Roche and Carmot — acquisition and enicepatide
Roche's December 2023 acquisition announcement identified CT-388 among several Carmot clinical programs. The announced consideration included an upfront purchase price and contingent milestones. That portfolio transaction should not be reported as a compound-specific research allocation. Current Roche releases identify CT-388 as enicepatide, while registry records also retain RO7795068. Keeping those names connected prevents an ownership change from appearing to create a new compound. Roche acquisition announcement, Roche development update, September 22, 2026.
About this account
Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment. The development or financing event discussed in this update is dated 2026-05-15.